Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Genome-Wide Detection of DNA Hydroxymethylation in Various Cancer Types Using Nanopore Sequencing
EF 2022-23
Résumé
The aim of this project is to examine the DNA hydroxymethylation (5hmC) profiles of about 180 patients within the Personalized OncoGenomics (POG) program at BC Cancer to infer unique 5hmC signatures across different cancer types. Methylation of cytosine is a well-characterized and stable DNA modification that regulates gene expression through silencing gene promoters and enhancers. In comparison, 5hmC is a dynamic epigenetic modification synthesized by Ten-Eleven Translocation (TET) enzymes and converted to other intermediates, ultimately resulting in demethylation. Previous literature has shown 5hmC to be a unique biomarker for different cancer types. However, no efforts have been made to characterize 5hmC in cancer using nanopore sequencing. Currently, our lab has done preliminary analysis of nanopore 5hmC calling and have found promising results with Nanopore Technologies neural network models. These models have shown to detect 5hmC in synthetic DNA and to correlate with oxidative bisulfate sequencing results. A pipeline workflow will be developed to run 5hmC calling on the complete nanopore sequencing dataset of POG patients. The 5hmC signatures of each patient sample will be profiled specifically looking for regions of differential 5hmC across cancer types. This dataset contains several cancers with mutations in demethylation pathways such as TET1, TET2, and IDH1. It is hypothesized that these cancers will show distinctive 5hmC clustering. Further, 5hmC profiles could be compared to our lab’s whole transcriptome and methylome data for these tumors. This project will shed light on 5hmC biomarkers for specific cancer types as well as the epigenetic implications of mutations in enzymes involved in DNA methylation regulation.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486378
Name
Galbraith Andrew J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Genome-Wide Detection of DNA Hydroxymethylation in Various Cancer Types Using Nanopore Sequencing
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Biomarkers; Cancer; Demethylation; Epigenetics; Hydroxymethylation; Nanopore Sequencing; Oncogenomics; Precision Medicine; Whole Genome Sequencing
Abstract
The aim of this project is to examine the DNA hydroxymethylation (5hmC) profiles of about 180 patients within the Personalized OncoGenomics (POG) program at BC Cancer to infer unique 5hmC signatures across different cancer types. Methylation of cytosine is a well-characterized and stable DNA modification that regulates gene expression through silencing gene promoters and enhancers. In comparison, 5hmC is a dynamic epigenetic modification synthesized by Ten-Eleven Translocation (TET) enzymes and converted to other intermediates, ultimately resulting in demethylation. Previous literature has shown 5hmC to be a unique biomarker for different cancer types. However, no efforts have been made to characterize 5hmC in cancer using nanopore sequencing. Currently, our lab has done preliminary analysis of nanopore 5hmC calling and have found promising results with Nanopore Technologies neural network models. These models have shown to detect 5hmC in synthetic DNA and to correlate with oxidative bisulfate sequencing results. A pipeline workflow will be developed to run 5hmC calling on the complete nanopore sequencing dataset of POG patients. The 5hmC signatures of each patient sample will be profiled specifically looking for regions of differential 5hmC across cancer types. This dataset contains several cancers with mutations in demethylation pathways such as TET1, TET2, and IDH1. It is hypothesized that these cancers will show distinctive 5hmC clustering. Further, 5hmC profiles could be compared to our lab’s whole transcriptome and methylome data for these tumors. This project will shed light on 5hmC biomarkers for specific cancer types as well as the epigenetic implications of mutations in enzymes involved in DNA methylation regulation.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Galbraith, Andrew J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~